Elasticsearch Open Inference API Now Supports Microsoft Azure AI Studio

Developers can now natively use the Elasticsearch vector database to store and utilize embeddings from models hosted on Azure AI Studio

SAN FRANCISCO--(BUSINESS WIRE)-- Elastic (NYSE: ESTC) today announced the Elasticsearch open inference API supports integration with the model catalog hosted in Microsoft Azure AI Studio. This includes native support for the Elasticsearch vector database to store and utilize embeddings from a wide selection of models, including those developed by Open AI and Mistral.

“Developers want choice and flexibility when it comes to the tools, solutions, and models they leverage, and this deeper integration provides exactly that to those in the Azure ecosystem,” said Shay Banon, co-founder and chief technology officer at Elastic. “With native access to Azure OpenAI Service and a broad catalog of models in the Azure AI Studio, developers can use the vast capabilities of Elasticsearch, the world’s most downloaded vector database, to completely transform their conversational search experience.”

Support for Azure AI Studio is available today, read the Elastic blog to get started.

About Elastic

Elastic (NYSE: ESTC) enables everyone to find the answers they need in real-time using all their data, at scale. Elastic’s solutions for search, observability and security are built on the Elastic Search AI Platform, the development platform used by thousands of companies, including more than 50% of the Fortune 500. Learn more at elastic.co.

Elastic and associated marks are trademarks or registered trademarks of Elastic N.V. and its subsidiaries. All other company and product names may be trademarks of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240522472894/en/

Elastic Global PR
[email protected]

Source: Elastic N.V.

You May Also Be Interested In

• Maurel & Prom: Activity for the First Half of 2026
• Qarbon Aerospace Expands Classified Defense Capabilities at Red Oak, Texas Headquarters
• Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)